PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab

被引：4

作者：

Dahagam, Chanukya ^{[1
]}

Goud, Aditya ^{[1
]}

Abdelqader, Abdelhai ^{[1
]}

Hendrani, Aditya ^{[2
]}

Feinstein, Matthew J. ^{[3
]}

Qamar, Arman ^{[4
]}

Joshi, Parag H. ^{[5
]}

Swiger, Kristopher J. ^{[6
]}

Byrne, Kathleen ^{[7
]}

Quispe, Renato ^{[8
]}

Jones, Steven R. ^{[8
]}

Blumenthal, Roger S. ^{[8
]}

Martin, Seth S. ^{[8
]}

机构：

[1] MedStar Franklin Sq Med Ctr, Dept Med, Baltimore, MD USA

[2] MedStar Good Samaritan Union Mem Hosp, Dept Med, Baltimore, MD USA

[3] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA

[4] Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA

[5] Univ Texas Southwestern Med Ctr Dallas, Div Cardiovasc, Dallas, TX 75390 USA

[6] Vanderbilt Univ, Div Cardiovasc, Med Ctr, Nashville, TN USA

[7] Johns Hopkins Univ Hosp, Pediat Cardiol, Baltimore, MD 21287 USA

[8] Johns Hopkins Univ, Sch Med, Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Div Cardiol,Dept Med, 600 North Wolfe St,Carnegie 591, Baltimore, MD 21287 USA

来源：

FUTURE CARDIOLOGY | 2016年 / 12卷 / 02期

关键词：

alirocumab; evolocumab; LDL; monoclonal antibodies; PCSK9; inhibitors; statin intolerance;

D O I：

10.2217/fca.15.88

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this review, we examine alirocumab (Praluent (R)), a monoclonal antibody to PCSK9 and its role in reducing LDL-C levels. By comparing the results of various studies and trials we discuss the efficacy and safety of alirocumab. We aim to guide clinicians of the role of alirocumab in clinical practice. Overall, PCSK9 inhibitors are promising new agents in further reducing LDL-C levels in addition to diet and maximally tolerated statin therapy. Long-term outcome studies are currently ongoing and will further delineate the role of PCSK9 inhibitors.

引用

页码：149 / 157

页数：9

共 39 条

[1]

[Anonymous], 2015, PRAL AL

[2]

[Anonymous], 2015, REP EV

[3] Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel [J].

Banach, Maciej ;

Rizzo, Manfredi ;

Toth, Peter P. ;

Farnier, Michel ;

Davidson, Michael H. ;

Al-Rasadi, Khalid ;

Aronow, Wilbert S. ;

Athyros, Vasilis ;

Djuric, Dragan M. ;

Ezhov, Marat V. ;

Greenfield, Robert S. ;

Hovingh, G. Kees ;

Kostner, Karam ;

Serban, Corina ;

Lighezan, Daniel ;

Fras, Zlatko ;

Moriarty, Patrick M. ;

Muntner, Paul ;

Goudev, Assen ;

Ceska, Richard ;

Nicholls, Stephen J. ;

Broncel, Marlena ;

Nikolic, Dragana ;

Pella, Daniel ;

Puri, Raman ;

Rysz, Jacek ;

Wong, Nathan D. ;

Bajnok, Laszlo ;

Jones, Steven R. ;

Ray, Kausik K. ;

Mikhailidis, Dimitri P. .

ARCHIVES OF MEDICAL SCIENCE, 2015, 11 (01) :1-23

[4] Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial [J].

Bays, Harold ;

Gaudet, Daniel ;

Weiss, Robert ;

Ruiz, Juan Lima ;

Watts, Gerald F. ;

Gouni-Berthold, Ioanna ;

Robinson, Jennifer ;

Zhao, Jian ;

Hanotin, Corinne ;

Donahue, Stephen .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (08) :3140-3148

[5] An assessment by the Statin Liver Safety Task Force: 2014 update [J].

Bays, Harold ;

Cohen, David E. ;

Chalasani, Naga ;

Harrison, Stephen A. .

JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (03) :S47-S57

[6] PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment? [J].

Cainzos-Achirica, Miguel ;

Martin, Seth S. ;

Cornell, John E. ;

Murow, Cynthia D. ;

Guallar, Eliseo .

ANNALS OF INTERNAL MEDICINE, 2015, 163 (01) :64-65

[7] Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial [J].

Cannon, Christopher P. ;

Cariou, Bertrand ;

Blom, Dirk ;

McKenney, James M. ;

Lorenzato, Christelle ;

Pordy, Robert ;

Chaudhari, Umesh ;

Colhoun, Helen M. .

EUROPEAN HEART JOURNAL, 2015, 36 (19) :1186-1194

[8]

Ezzahti M, 2013, NETH J MED, V71, P227

[9]

Ginsberg HN, 2014, CIRCULATION, V130, P2119

[10]

Giunzioni I, 2013, AHA SCI SESSION S, V128

← 1 2 3 4 →